Geron Corporation (GERN)
NASDAQ:GERN
Want to see GERN full AI Analyst Report?
GERN Stock Chart & Stats
$1.68
<$0.01(0.15%)
At close: 4:00 PM EST
$1.68
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$1.04 - $2.01
Previous CloseN/A
Volume1.63M
Average Volume (3M)14.00M
Market Cap
$808.32M
Enterprise Value$970.13M
Total Cash (Recent Filing)$314.29M
Total Debt (Recent Filing)$251.84M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Aug 06, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding641,521,000
10 Day Avg. Volume14,462,172
30 Day Avg. Volume14,003,425
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue4.95
Enterprise Value/Gross Profit5.71
Enterprise Value/Ebitda-26.26
Forecast
1Y Price Target
$4.00Price Target Upside138.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$233.75M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained commercial uptake is shown by meaningful quarterly and annual revenue gains and reiterated 2026 guidance. This revenue ramp supports scale economics, funds ongoing commercialization, and provides multi‑quarter visibility that strengthens the company's ability to invest in growth.
Clinical ProgressA fully enrolled Phase III with a near‑term interim creates a structural de‑risking path for the lead program. Positive interim results and peer‑reviewed publications enhance scientific credibility and could materially expand label, informing durable adoption and long‑term revenue opportunity.
Balance Sheet CushionA meaningful equity base and manageable leverage provide a structural financial buffer versus pure early‑stage peers. This capital structure increases runway to execute commercial and clinical plans, enabling strategic investments while retaining flexibility for financing or partnerships if needed.
Bears Say
Cash BurnPersistent negative operating and free cash flow indicate the company is not yet self‑funding and remains reliant on existing liquidity or external financing. Continued cash burn over multiple quarters elevates financing risk and could constrain strategic choices if revenues underperform.
Gross-to-Net PressureRising gross‑to‑net reductions materially lower realized revenue per unit and compress margins. Structural drivers like increased 340B utilization and GPO contracting suggest sustained headwinds to net pricing, which can persistently erode revenue conversion despite volume growth.
Europe Commercialization UncertaintyUnsettled ex‑U.S. strategy delays diversification of revenue and limits upside from international markets. Without a clear partner or pricing pathway, European commercialization timelines and scale remain uncertain, concentrating execution risk on the U.S. market in the medium term.
Geron News
GERN FAQ
What was Geron Corporation’s price range in the past 12 months?
Geron Corporation lowest stock price was $1.04 and its highest was $2.01 in the past 12 months.
What is Geron Corporation’s market cap?
Geron Corporation’s market cap is $808.32M.
When is Geron Corporation’s upcoming earnings report date?
Geron Corporation’s upcoming earnings report date is Aug 06, 2026 which is in 44 days.
How were Geron Corporation’s earnings last quarter?
Geron Corporation released its earnings results on May 06, 2026. The company reported -$0.01 earnings per share for the quarter, beating the consensus estimate of -$0.02 by $0.01.
Is Geron Corporation overvalued?
According to Wall Street analysts Geron Corporation’s price is currently Undervalued.
Does Geron Corporation pay dividends?
Geron Corporation does not currently pay dividends.
What is Geron Corporation’s EPS estimate?
Geron Corporation’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corporation have?
Geron Corporation has 641,521,000 shares outstanding.
What happened to Geron Corporation’s price movement after its last earnings report?
Geron Corporation reported an EPS of -$0.01 in its last earnings report, beating expectations of -$0.02. Following the earnings report the stock price went down -4.242%.
Which hedge fund is a major shareholder of Geron Corporation?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.00 (138.10% Upside)
$4.00 (138.10% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.70%
12-Months-Change
Fundamentals
Return on Equity
-28.90%
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Company Description
Geron Corporation
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive operational and commercial story: strong revenue growth (+31% YoY), expanding demand (+6% QoQ) and disciplined cost reductions position Geron to meet 2026 guidance. Important clinical and regulatory milestones (IMpactMF enrollment, NCCN order template inclusion, peer-reviewed publication) bolster the long-term value proposition. Key risks highlighted include widening gross-to-net pressure (21% vs 13% prior year), a meaningful quarter-over-quarter cash decline (~$60M) driven by one-time and supply investments, and unresolved European commercialization/pricing decisions. On balance, the favorable revenue trajectory, cost discipline and clinical progress outweigh the manageable near-term financial and market-access headwinds.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$4.00
▲(138.10% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
10.92% Mutual Funds
35.26% Other Institutional Investors
38.19% Public Companies and
Individual Investors